(CNN) – A new study published in the New England Journal of Medicine suggests that the vaccine against the cofid-19 of Pfizer / BioNTech could protect people against the new variants of coronavirus, including one that was first seen in South Africa called B .1,351.
For the study, researchers from Pfizer and the University of Texas Medical Center are designing versions of the genetic engineering median virus to carry some of the mutations found in B.1,351. The tests were performed with samples from 15 people who had received doses of the Pfizer / BioNTech vaccine as part of a clinical trial.
If the strains of his blood sang well, he would reduce its activity of neutralizing anticoagulants, which would be sufficient to neutralize the virus, writing it on a card to the magazine. This is online with other studies. It also enters into what it is with other viruses, one of the investigators.
“Although we do not know exactly what level of neutralization is required for protection against infection or infection by covid-19, our Experience with other vacancies we know that it is probable that the Pfizer vaccine provides a Scottish protection. , director of the Instituto de Infecciones e Inmunidad Humana de la Rama Médica de la Universidad de Texas, and the authority of the study.
“The reduction in the levels of neutralization against the South African variant of approx. », Aggregated by Weaver.
What Pfizer says about its vacancies and variants
Pfizer says that there is no evidence in real life that the variant escapes the protection that is offered to the vacancy. “However, Pfizer and BioNTech are in the process of reviewing the required conversions and enabling the appropriate conversions with the controllers to be and conditions to unregister and wait for authorization to trigger an ARNm alert », Pfizer dijo in a communication.
Separately, a team from the National Institutes of Health and Modernity will publish a map in the same magazine that describes the hallucinations of an experiment that reports my past. We will also report a reduction in the response to antiviral and genetically modified viruses to appear in variant B.1,351, but not a sufficient reduction for the vaccine to function with less efficacy.
“Because of this reduction, the levels of neutralization concentration with (the variant discovered in South Africa) are permanently due to the levels that will be protected”, the company said in a statement.
We will not find a reduction in the friction in front of a variant variant for the first time in the United Kingdom and known as B.1,1.7.